Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
32071430
PubMed Central
PMC7387295
DOI
10.1038/s41375-020-0749-5
PII: 10.1038/s41375-020-0749-5
Knihovny.cz E-zdroje
- MeSH
- adenin analogy a deriváty MeSH
- B-buněčný lymfom mortalita terapie MeSH
- dítě MeSH
- imunoterapie MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- mladiství MeSH
- piperidiny MeSH
- předškolní dítě MeSH
- pyrazoly škodlivé účinky farmakokinetika terapeutické užití MeSH
- pyrimidiny škodlivé účinky farmakokinetika terapeutické užití MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adenin MeSH
- ibrutinib MeSH Prohlížeč
- piperidiny MeSH
- pyrazoly MeSH
- pyrimidiny MeSH
Clinical Oncology Janssen R and D LLC High Wycombe UK
Clinical Oncology Janssen R and D LLC Raritan NJ USA
Clinical Pharmacology Janssen R and D LLC San Diego CA USA
Department of Child and Adolescent Cancer Gustave Roussy Paris France
Department of Pediatric Hematology and Oncology Ankara University Ankara Turkey
Department of Pediatric Oncology Gazi University Ankara Turkey
Pediatric Hematology and Oncology University Hospital Münster Münster Germany
Zobrazit více v PubMed
Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;52:177–81. doi: 10.1002/pbc.21753. PubMed DOI PMC
Cairo M, Auperin A, Perkins SL, Pinkerton R, Harrison L, Goldman S, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol. 2018;182:859–69. doi: 10.1111/bjh.15491. PubMed DOI PMC
Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol. 2019;185:1071–85. doi: 10.1111/bjh.15734. PubMed DOI
Woessmann W, Zimmermann M, Burkhardt B, Meinhardt A, Rosenbusch C, Vaillant V, et al. Relapsed or refractory Burkitt lymphoma in children and adolescents after BFM-type first-line therapy-a BFM group report. Blood. 2014;124:1738. doi: 10.1182/blood.V124.21.1738.1738. DOI
Woessmann W, Zimmermann M, Meinhardt A, Müller S, Hauch H, Knörr F, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020. 10.1182/blood.2019003591 [Epub ahead of print]. PubMed
Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, et al. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann NY Acad Sci. 2015;1358:82–94. doi: 10.1111/nyas.12878. PubMed DOI
Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, et al. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology. 2019;8:e1512455. doi: 10.1080/2162402X.2018.1512455. PubMed DOI PMC
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92. doi: 10.1038/nature08638. PubMed DOI PMC
Schaffer M, Chaturvedi S, Davis C, Aquino R, Stepanchick E, Versele M, et al. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. Leuk Lymphoma. 2018;59:931–40. doi: 10.1080/10428194.2017.1349899. PubMed DOI
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94. doi: 10.1200/JCO.2012.42.7906. PubMed DOI PMC
Sauter CS, Verwys SL, McCall SJ, Miller ST, Courtien AI, Schoder H, et al. Phase I study combining ibrutinib with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588. Blood. 2016;128(Suppl 1):4198. doi: 10.1182/blood.V128.22.4198.4198. DOI
IMBRUVICA (ibrutinib). [Prescribing information]. Horsham, PA: Pharmacyclics LLC; Sunnyvale, CA: Janssen Biotech, Inc; 2018.
de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharm Ther. 2016;100:548–57. doi: 10.1002/cpt.419. PubMed DOI
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
